The Minister for Industry, Science and Technology, the Hon Karen Andrews MP announced successful applications under the Business Research and Innovation Initiative (BRII).
WEJUGO shared in more than $1.4 million worth of funding to undertake a feasibility study on an innovative solution we have proposed to solve government policy and service delivery challenges in the tourism sector.
Have you ever wanted to know what it’s like to work in a startup? Get behind the scenes of three startups at different stages of their entrepreneurial journey and see where working in this dynamic space could take you.
Designed by Sydney School of Entrepreneurship in collaboration with the Sydney Startup Hub, this virtual internship gives you real life problems and supports you as you come up with innovative solutions that could make a real difference.
This program is open to anyone and everyone interested in the startup lifecycle!
Kitfit was selected by ++PwC’s Emerging Company team++ as a company with fast growth potential. PwC has collaborated with Kitfit to help ensure a successful launch and growth phase of the business. This work involves an interrogation of our business model and cash flow forecasting and seed round capital raise partnership.
In April 2017, as part of our commercial testing phase, we filed an Australian Trademark application for Kitfit which was approved in Nov 2017 and we immediately registered for international Trademark Status under the Madrid Protocol via WIPO.
In 2018 we successfully pursued a Notice of Suspension for a competing mark to obtain the broadest possible terms for our Kitfit US trademark, the application was finalised in January 2018. Following the registration of our US trademark, we have been able to successfully shut down 12 social media accounts on Facebook and Instagram as well as one iOS app that was infringing on our brand IP. This is excellent confirmation of IP protection strategy.
We have also received preliminary feedback from IP Australia on the viability of patenting three core technology innovations we have developed through our R&D process in 2018.
For now, these will be 'black boxed' to protect our IP, but we plan to investigate local and global patients with the potential to use grant funding for eligible businesses across a range of commercial project expenditure including trademarks and patents.
We are excited to announce that we have signed an MVP partnership with Rapha, the worlds largest premium cycling apparel retailer. This gives us the option to test the Kitfit MVP on our target audience in partnership with a global brand. As the market leader, Rapha is the benchmark of success and innovation for cycling retailers worldwide.
We became a leading global cycling kit community on Instagram in 8 months based on total followers, average account likes and engagements (Likes & comments) surpassing cycling vertical channel partners like Wiggle, ChainReaction and Bikeexchange.
Viral growth mechanism tested.
36K of sales generated
Reduced return rate from 20% to <1% through interacting with customers & identifying their key signals for fit.
51% gave personal fit data in Fit survey. 32% completed all of the kit and fit questions
The AgriFutures program will support 7 secondary schools in rural and regional Australia to connect with industry, government and tertiary education providers and solve problems facing the agricultural industry both locally and globally. It will also help young people explore the career possibilities available to them in the industry.
The 'Local Schools for Local Industry' Initiative will be supporting 20 secondary schools in regional NSW solve problems facing current and emerging local industries whilst equipping young people with skills for future work.
"We've created the first all-in-one solution that simplifies how businesses can market themselves to grassroots sports with measurable returns," Sportility Co-Founder, Adam Hyman said.
In this article,** [The Australian Financial Review**](https://www.linkedin.com/company/1628885/) shares Sportility's current and future goals, made possible by our valued investors, including Andrew Bogut, Josh Childress, Pelorus Private Equity and Prime Time Sports Management.
Sports media startup, Basketball Forever drove more engagements on Facebook during the 2019 NBA Playoffs than its competitive set, including the NBA and ESPN.
BF drove over 16.2m actions during the period 13th April -14th June 2019, beating the NBA at 14.3m, ESPN at 13.6m and Bleacher Report at 15.8m, according to analytics provided by third-party social analytics firm Sharablee.
Avirida zero-plastic skincare has received funding of $25,000 from the NSW government to produce their innovative patent-pending timber pots as an alternative to plastic & glass in the skincare industry, and provide jobs in regional NSW in the process. You can find out more about Avirida at ++www.avirida.com++
On the 17 August 2017, the Minister for Skills on behalf of the Jobs for NSW Fund approved our Minimum Viable Product grant and awarded RooCreate with $25,000.00 to develop a online platform dedicated to offering environmentally friendly product packaging and design.
Sofiri is out to shake up the international education sector with a new online service linking aspiring students with education experts to help them study abroad. Read about our support from hashtag#JobsForNSW to make our aspirations for international students a reality. Read more here http://bit.ly/2FKT2NA
Sportility recently featured on Sky News Australia's new show 'The Business of Sport'. The segment was also featured on FOX SPORTS Australia and focused on Sportility's mission to grow grassroots sports and democratise sports sponsorship globally.
A final year medicine student at the University of New South Wales (UNSW) has designed an artificial intelligence (AI) system that's helping women become pregnant using IVF techniques.
UNSW said on Wednesday that Aengus Tran, 24, and his MBA- accredited brother Dimitry have founded Harrrison-AI, an organisation that uses machine learning technology to improve the embryo selection process.
The men were driven to start the company following a lecture from IVF Australia’s scientific director, Dr Simon Cooke, who said that embryologists manually assess groups of embryos based on physical appearance at a limited number of critical development checkpoints. This is before they select the embryo they feel is most likely to result in a pregnancy, UNSW said.
Tran has created a system called ‘Ivy’ that uses machine learning from thousands of previous successful and unsuccessful embryos to help make decisions about viability faster and better.
Ivy is a ‘self-improving' AI that continuously learns from the embryos it analyses using a three dimensional assessment of growth of the embryos through all stages of development in an incubator. It then relates this data to whether a fetal heart has developed or not, UNSW said.
“Ivy has taught itself how to select out an embryo with the highest potential to create a fetal heart,” said Tran. “It starts off with a completely blank canvas and it’s not influenced by any previous human knowledge or bias. It has learnt directly from thousands of embryos that have had a known fetal heart outcome and has slowly and steadily improved itself to become better and better at selecting embryos.”
Harrison-AI is also hoping to use its technology to help patients who suffer from lung problems and eye disease.
With lung disease, the problem is in detecting tuberculosis, Dimitry Tran said.
“We’re specifically working on how to put this technology in the hands of doctors in Vietnam. We don’t just want to write a paper or go to a conference and talk about this technology – we really want to make a difference to how people treat this disease and help patients,” he said.
“In the past, people used to talk about the Trifecta problem. You could not have something that was very fast, very good and very cheap – you could also pick two of those to be correct. But now for the first time with AI, it is possible to be fast, accurate and cheap.”
UNSW said Harrison-AI has struck a deal with IVF service provider Virtus Health to introduce Ivy across its clinics Australia-wide and across Europe later this year.
This is not the first time AI technologies have been used to improve IVF outcomes. In April, American IVF service said it was working with Australian AI company Life Whisperer on a retrospective study to assess whether AI could have identified embryos that would have led to a successful pregnancy.
Sydney, Australia - Virtus Health, (“Virtus”, ASX: VRT) Australia and Ireland’s largest Assisted Reproductive Services(ARS) provider announces that it has entered into transfer and collaboration agreements for its Artificial Intelligence software “Ivy” with Vitrolife based in Sweden, the manufacturer of EmbryoScope time lapse incubators and Harrison.AI, an Australian technology company specialising in AI in healthcare.
The agreements comprise two main components:
Transfer to Vitrolife of intellectual property and patent applications (“IP”)relating to the Ivy AI technology from the current owners, Virtus Health and Harrison. AI, responsible for the development; and
Collaboration agreements between the parties for an initial period of three years to ensure further development of the technology in the time-lapse incubator application.
The initial payment from Vitrolife relating to the transfer of the IP is USD 6 million. In addition to the initial purchase price, additional payments of up to USD 2 million may be paid in relation to the achievement of product development targets over the next three years. Virtus Health will share all revenue amounts equally with Harrison. The financial benefits of the entire collaboration will be recognised over a three year period.
Using time-lapse images during in vitro fertilisation (“IVF”) and before embryo transfer the Ivy technology can predict the likelihood of an embryo developing a foetal heart and viable pregnancy.
The artificial intelligence technology will support elective single embryo transfer and is anticipated to shorten the time to pregnancy by helping IVF practitioners rank the most viable embryos for selection and transfer.
“Together with Harrison. AI we are delighted to announce the collaboration with Vitrolife. The development of Ivy with Harrison. AI has been an exciting project which we believe will make a significant contribution to patient care and outcomes”, said Sue Channon Group CEO Virtus Health. “We believe Ivy is the most advanced tool of its kind in human embryology. Artificial Intelligence technology is likely, in the future, to be the dominant embryo selection method used in IVF”.
Virtus scientific teams are working closely with the Harrison. AI team to implement Ivy in Virtus Health clinics equipped with Vitrolife’s time lapse incubators, EmbryoScope+.
“The formal agreements build on existing scientific and commercial relationships and will focus on further innovation in the field of assisted reproductive technology,” said Sue Channon.
Vitrolife is the market leader in time-lapse incubation systems for use in assisted reproduction, providing undisturbed culture and improved selection of embryos. “We are delighted to announce the collaboration with Virtus Health and Harrison. AI to develop and market a state-of-the-art AI technology for the EmbryoScope timelapse systems”, says Thomas Axelsson, CEO of Vitrolife.
International medical and scientific community interest is growing in the innovative Australian technology which uses artificial intelligence to predict the likelihood of an individual IVF embryo leading to a viable pregnancy, with publication of early findings in the world’s leading peer-reviewed journal for fertility health, ++Human Reproduction++.
“It is becoming increasingly clear that Artificial Intelligence technology will, in future, be the dominant embryo selection method used in IVF,” said A/Prof Peter Illingworth, Medical Director IVFAustralia, Virtus Health, where Ivy AI was pioneered in collaboration with Harrison.AI.
Evaluation of the technology was conducted in Virtus Health clinics on data obtained from 10,638 embryos. These data were based on embryos cultured in time-lapse incubators from eight different IVF clinics, across four different countries, between January 2014 and December 2018. The findings were originally presented in October 2018 at the American Society of Reproductive Medicine Annual Conference and a manuscript published in Human Reproduction today.
“Now with the Ivy AI technology we can take advantage of the ability of AI to process an enormous amount of data, too much for a human to process, to more accurately and objectively predict the best embryo to select for transfer, based on the presence of a fetal heart,” said A/Prof Illingworth.
Previous forms of this technology have shown a good correlation with a skilled embryologist but IVY is the first Artificial Intelligence system to actually predict fetal heart rate outcomes solely from study of the embryonic development.
“The next step is to carry out clinical studies, including a planned randomised trial to better understand the clinical role of this powerful technology and, in particular to find out what contribution, if any, it can make to improving success rates in IVF. This technology has the potential to contribute to IVF medicine by shortening the time to a successful pregnancy and increasing IVF pregnancy rates and while we believe that Ivy AI is the most advanced tool of its kind in human embryology, this still needs further evaluation through a randomised controlled trial.” said A/Prof Peter Illingworth.
“Ivy is a self-improving AI tool that continuously learns from embryos that it analyses. The AI iteratively retrains on powerful supercomputers and has been shown to consistently improve on previous versions of itself in identifying the embryo with the highest potential for a successful pregnancy” said Aengus Tran, Medical AI Director at Harrison.AI. “As with many other areas of medicine, this is a demonstration of the potential for artificial intelligence to make an enormous contribution to human health.”
In April, Virtus Health and Harrison.AI announced a collaboration with the Swedish company, Vitrolife, the world’s leader in time lapse incubation systems, to further develop the pioneering system.
Sportility, the fastest growing sports-tech startup in Australia, was named ‘Startup of the Year’ at the prestigious NSW iAwards last night.
The iAwards is Australia's longest running and most broadly scoped innovation recognition program, promoting excellence in the Australian digital ecosystem from the likes of Google Maps to Atlassian and Wotif.
Sportility co-founder and CEO, Adam Hyman highlighted that they were delighted to be acknowledged with the win.
“We are incredibly proud to be recognised as Startup of the Year by such a notable association. Our team has worked hard to create a first-of-its-kind platform that is set to shake up the sports sponsorship industry in Australia and beyond.”
Sportility is the first and only platform in the world that is levelling the playing field in sports sponsorship by connecting brands to amateur teams, granting them access to affordable, professional gear. Teams simply log on to Sportility, design their custom gear and add participating sponsor logos to reduce their costs by up to 40%.
“Sports sponsorship is a sought-after opportunity for so many businesses but often these are restricted to big brands with big budgets. Through Sportility, not only do grassroots sporting teams have the opportunity to reduce costs, but businesses of all sizes have access to cost-effectively engage with a highly untapped, engaged audience. It’s a win-win,” said Hyman.
Since its launch in 2017, co-founders Adam Hyman and Dan Harsanyi have grown the business to employ a staff of 20 and have already signed on more than 60,000 members to the platform. In March this year, they welcomed NBA Champion and NBL’s Most Valuable Player, Andrew Bogut as both an investor and ambassador for the business.
They say finding Product Market Fit can be known as a feeling. 'You just know when you've found it'. After more than 2 years! I can say that we have found it and it the results are supporting it. The journey has has only just begun.
We entered into a pitch comp at the last second, and managed to take it down! All expenses paid for trip to China, where we can progress to the global finals of OTEC, access new markets and also talk to manufacturing partners too!